Group to carry out safety production cross-industry exchange inspection
Release time:
2020-07-22
Mutual Check Mutual Learning Mutual Improvement
Group Launching Cross-industry Exchange Inspection on Safety Production
News In order to further investigate potential safety hazards and improve the level of safety production management, it is an opportunity for safety supervisors of various units to come to Jinhua to participate in safety knowledge competitions, 6 May 11 and 12 , led by Li Xiaoyin, director of the safety management office of the group company, the safety and environmental protection personnel from Yunnan Jianfeng, Daye Jianfeng, Pharmaceutical Company, Jianfeng Health, Cable Company, Shanghai Beika and other units formed an inspection team to conduct cross-industry exchange inspections on safety production at Jinxi Factory of Jianfeng Pharmaceutical Factory and International Trade Company.
In the Jinxi factory area of the pharmaceutical factory, the inspection team was divided into two groups. The on-site inspection team focused on the detailed inspection of workshop equipment and facilities, fire fighting equipment testing, sewage treatment, warning signs, explosion-proof and anti-static facilities for hazardous chemicals, etc. The ledger inspection team consulted the data on the aspects of emergency plan update, double prevention data improvement, hazard source control, special operation personnel holding certificates, hidden danger rectification tracking, etc, while looking for hidden dangers and deficiencies, everyone exchanged their management experiences.
In the e-commerce boutique park of the International Trade Company, through on-site inspection of the park, the inspection team put forward suggestions and suggestions on the insulation measures of distribution lines, signs, fire-fighting facilities and equipment testing, equipment equipment equipment, vehicle parking and so on. The inspectors also carefully looked through the safety management ledger, and had in-depth exchanges on the signing of safety agreements, personnel qualification filing, daily maintenance and maintenance of special equipment, personnel safety operation procedures, lightning protection and anti-static detection, and the diversion of people and vehicles in the park.
Li Xiaoyin said that the purpose of this cross-industry exchange inspection is to enhance the safety management exchange between brother units. Through cross-checking, the safety and environmental protection personnel of each unit can find out the bright spots and places worth learning in the daily management of brother units while looking for potential safety hazards, so as to achieve the purpose of mutual learning and mutual improvement. From this inspection, the safety production work of each unit is generally in good condition, especially the warehouse safety management of international trade companies has improved a lot. Safety production is the lifeline of an enterprise, and all units should humbly accept the opinions and suggestions put forward in this inspection, rectify and improve them in time, and at the same time take this activity as an opportunity to strengthen mutual exchanges and learning, and build a solid defense line for production safety.
The safety and environmental protection personnel who participated in this inspection also said that this type of cross-industry cross-inspection has established a good communication platform between various units, which is conducive to the continued in-depth exchange of management experience between each other. Safety and environmental protection work has a great role in promoting. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page